Aducanumab
Based on 1 Customer Validation
Aducanumab (BIIB037) is a human monoclonal antibody that selectively targets aggregated amyloid-beta (Aβ). Aducanumab shows blood-brain-barrier penetration, and can be used for Alzheimer's disease (AD) research.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 99.25%
- CAS No.: 1384260-65-4
- 분자량:146.2 kDa
-
보관:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
제품 설명
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
Amyloid Beta/Aβ
In Vivo
Aducanumab (0.3-30 mg/kg, i.p., weekly, 6 months) reduces soluble and insoluble Aβ in a dose-dependent manner in 9.5- to 15.5-month-old Tg2576 transgenic mice[1].
Aducanumab (10 mg/kg, i.p., weekly, 6 months) restores intracellular calcium to control levels in 18-month-old Tg2576 mice[2].
Aducanumab (0.4-1 mg/mL, ICV, 20 min) leads to rapid decrease in amyloid burden, plaque clearance in Tg2576 mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:9.5- to 15.5-month-old Tg2576 transgenic mice [1]
-
Dosage:0.3-30 mg/kg
-
Administration:Intraperitoneal injection (i.p.), weekly, 6 months
-
Result:Increased recruitment of Iba-1-positive microglia to Aβ plaques.
-
Animal Model:18-month-old Tg2576 mice[2]
-
Dosage:10 mg/kg
-
Administration:Intraperitoneal injection (i.p.), weekly, 6 months
-
Result:Restored neurite baseline calcium to control levels.
Decreased the number of neurites with elevated levels of calcium after 2 weeks.
Decreased the percentage of cell bodies with calcium overload.
Restored the levels of VILIP and SERCA to control levels.
Increased the cell numbers of NR1 and NR2A.
-
Animal Model:22-month-old transgenic Tg2576 mice[2]
-
Dosage:0.4-1 mg/mL
-
Administration:Intracerebroventricular injection (ICV), 20 min
-
Result:Decreased the number of amyloid plaque.
Decreased the size of the remaining individual plaques.
Reduced amyloid plaque burden.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
신청
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Human Beta-amyloid/Beta-APP Protein (hFc Tag) can bind Aducanumab. The EC50 for this effect is 603.66 ng/mL. -
The EC50 for this effect is 603.66 ng/mL. Flow cytometric analysis of 1.5×106 HUVEC cells with Aducanumab (HY-P9967, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa, Isotype Control (HY-P99001, blue) was used as the isotype control.
Chemical Information
-
CAS No. 1384260-65-4
-
Appearance Liquid
-
분자량 146.2 kDa
-
Color Colorless to light yellow
-
SMILES
[Aducanumab]
-
Synonyms
BIIB037
-
선적
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
-
Data Sheet (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Sevigny J, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature. 2016 Sep 1;537(7618):50-6. [Content Brief]
[2]. Kastanenka KV, et al. Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice. J Neurosci. 2016 Dec 14;36(50):12549-12558. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)